iShares Biotechnology ETF
415 hedge funds and large institutions have $6.44B invested in iShares Biotechnology ETF in 2015 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 145 increasing their positions, 140 reducing their positions, and 57 closing their positions.
4% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 140
2% less first-time investments, than exits
New positions opened: 56 | Existing positions closed: 57
2% less capital invested
Capital invested by funds: $6.6B → $6.44B (-$163M)
1% less funds holding
Funds holding: 420 → 415 (-5)
31% less funds holding in top 10
Funds holding in top 10: 42 → 29 (-13)
41% less call options, than puts
Call options by funds: $866M | Put options by funds: $1.47B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$377M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$298M |
| 3 |
Morgan Stanley
New York
|
+$272M |
| 4 |
Goldman Sachs
New York
|
+$179M |
| 5 |
Citigroup
New York
|
+$88.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Churchill Management
Los Angeles,
California
|
-$124M |
| 2 |
JP Morgan Chase
New York
|
-$102M |
| 3 |
SG
Swarthmore Group
Philadelphia,
Pennsylvania
|
-$37.3M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$22.3M |
| 5 |
ACM
Arlington Capital Management
Arlington Heights,
Illinois
|
-$21M |
IBB Hedge Fund Activity: Q3 2015 in Review
415 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q3 2015, worth a combined $6.44B — down 2.5% from $6.6B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of IBB and 56 opened new positions — a net loss of 1 holder — while 140 trimmed existing stakes and 145 added.
The largest buyer was Credit Suisse, adding an estimated $377M. The largest seller was Churchill Management, exiting entirely with an estimated $124M sold.
- 415 institutional investors held iShares Biotechnology ETF (IBB) as of Q3 2015, down from 420 in Q2 2015.
- Funds reported $6.44B of iShares Biotechnology ETF stock for Q3 2015, down 2.5% quarter-over-quarter.
- 56 funds opened new iShares Biotechnology ETF positions in Q3 2015 and 57 closed out, a net change of -1 holder.
- The largest iShares Biotechnology ETF buyer in Q3 2015 was Credit Suisse, an estimated $377M added.
- The largest iShares Biotechnology ETF seller in Q3 2015 was Churchill Management, an estimated $124M sold.
Based on aggregated 13F filings for Q3 2015.